Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Pain control: A human right?
3. Traditional view of cancer pain control
4. The importance of cancer pain control
5. Clinical practice guideline: Cancer pain
6. Cancer pain control - ABCDE
7. Assessing cancer pain
8. Sources of cancer pain
9. Matching pain mechanism to Rx
10. WHO ladder: Severity-based Rx
11. AHCPR pyramid + ribbon
12. Nonopioid analgesics (1)
13. Nonopioid analgesics (2)
14. Nonopioid analgesics (3)
15. Nonopioid analgesics (4)
16. Nonopioid analgesics (5)
17. Opioids
18. Opioids: Morphine dosing (1)
19. Opioids: Morphine dosing (2)
20. Opioids: Morphine
21. Opioids: Switching from morphine
22. Opioids: Opioid side effects
23. Opioids: Neuraxial route
24. Adjuvant analgesics: Introduction
25. Adjuvant analgesics: Anticonvulsants
26. Adjuvant analgesics: Antidepressants
27. Adjuvant analgesics: Miscellaneous
28. Other analgesic modalities
29. Barriers to cancer pain assessment, treatment
30. EBP - Evidence based practice
31. Maimonides on bias
32. Types of evidence
33. Evidence: Strength, consistency
34. Systematic reviews vs. narrative reviews
35. Agency for health care research and quality
36. AHRQ publications free for download
37. Background: EPC reviews
38. Marcus Aurelius on symptom clusters
39. Prevalence: Pain
40. Assessment: Pain
41. "Pain evidence": Problems
42. Treatment: Pain (1)
43. Treatment: Pain (2)
44. Treatment: Pain (3)
45. In an ideal world...
46. Cancer pain: Future research
47. Acknowledgments

Topics Covered

• Importance of cancer pain control
• Assessment and sources of cancer pain
• Selecting agents according to pain mechanism
• The WHO ladder
• Nonopioids and adjuvants
• Opioids
• Side effects
• Neuraxial drug delivery
• Nondrug modalities
• What does the published evidence show?

Links

Series:

• Cancer Pain Management

Categories:

• Cancer
• Diseases, Disorders & Treatments
• Neuroscience

Therapeutic Areas:

• Neurology
• Oncology

Talk Citation

Publication History

• Published on February 23, 2009

Financial Disclosures

• Prof. Daniel Carr has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.